79O.F NUGEN MEDICAL DEV. INC.
- Market cap
- EUR 2.04M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 79O.F undervalued?
Graham numberThe Graham number of NUGEN MEDICAL DEV. INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NUGEN MEDICAL DEV. INC. fundamental analysis
No fundamental analysis for NUGEN MEDICAL DEV. INC. yet.
NUGEN MEDICAL DEV. INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NUGEN MEDICAL DEV. INC.
NuGen Medical Devices Inc., a specialty medical device company, engages in developing and commercializing novel drug delivery technologies in Europe, Asia, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, vaccines, veterinary, home healthcare, and others. It also provides InsuJet that focuses on servicing the diabetic community; and V5, V6, V7, and V8 In…
Full company profileNUGEN MEDICAL DEV. INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NUGEN MEDICAL DEV. INC. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 138K | 152K | 331K | 1.01M | 258K | 59.6K |
| Gross Profit | 92.2K | 99.2K | 165K | 522K | 132K | 33.4K |
| Operating Income | -7.64M | -4.79M | -8.04M | -5.16M | -4.22M | -3.97M |
| EBITDA | - | -3.91M | -7.40M | -2.90M | -4.02M | -648K |
| Net Income | -7.11M | -5.58M | -9.36M | -5.23M | -7.83M | -5.25M |
| EPS | -0.08 | -0.06 | -0.05 | -0.02 | -0.03 | -0.02 |
| Balance Sheet | ||||||
| Total Assets | 8.84M | 6.85M | 6.95M | 12.9M | 4.29M | 2.04M |
| Total Liabilities | 7.19M | 9.11M | 9.01M | 18.6M | 18.0M | 19.2M |
| Shareholders' Equity | 1.66M | -2.26M | -2.06M | -5.67M | -13.7M | -17.1M |
| Cash & Short-term Investments | 1.75M | 131K | 464K | 6.95M | 3.14M | 701K |
| Cash Flow | ||||||
| Operating Cash Flow | -4.10M | -2.13M | -6.71M | -4.71M | -3.57M | -4.31M |
| Capital Expenditure | 3.57K | 1.01K | 3.02K | 10.4K | 302K | 671K |
| Free Cash Flow | -4.10M | -2.13M | -6.72M | -4.72M | -3.87M | -4.98M |
| Ratios | ||||||
| ROE | -428.7% | - | - | - | - | - |
| ROA | -80.4% | -81.4% | -134.8% | -40.5% | -182.4% | -257.2% |
| Net Profit Margin | -5,163.2% | -3,661.1% | -2,825.0% | -517.5% | -3,034.0% | -8,810.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NUGEN MEDICAL DEV. INC. dividends
NUGEN MEDICAL DEV. INC. has not paid dividends in the last 5 fiscal years.
Who owns NUGEN MEDICAL DEV. INC.
- Insiders 2.39%
- Institutions 0.00%
- Public & others 97.61%
- Shares outstanding 227M
- Free float 222M
NUGEN MEDICAL DEV. INC. company profile
- Company name
- NUGEN MEDICAL DEV. INC.
- Ticker
- 79O.F
- ISIN
- CA67054F1009
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 18 King Street East, Toronto, ON, Canada, M5C 1C4
- Phone
- 833 285 5557
- Website
- nugenmd.com
About NUGEN MEDICAL DEV. INC.
NuGen Medical Devices Inc., a specialty medical device company, engages in developing and commercializing novel drug delivery technologies in Europe, Asia, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, vaccines, veterinary, home healthcare, and others. It also provides InsuJet that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors. NuGen Medical Devices Inc. is based in Toronto, Canada.
NUGEN MEDICAL DEV. INC. management
5- Mr. Lin LiangCEO & Executive Chairman
- Mr. Nicky CantonExecutive VP & COO · born 1984
- Ms. Karen DunlapInterim Chief Customer Officer & Director · born 1948
- Mr. Ajay MishraCFO & Corporate Secretary
- Ms. Elisha DillonHead of Global Sales & Strategic Partnerships